Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Microglia-neuron communication in health and disease

NeuroTalk2Mi

Microglia are the resident immune cells of the brain, display extensive heterogeneity, and contribute to a wide range of cellular processes in both homeostasis and disease. They play a major role in the pathogenesis of Alzheimer’s disease (AD), the leading cause of dementia and a major cause of mortality worldwide. Microglia closely interact with...

Funding Programme
Start Date
End Date
Total Funding
€ 191 760
European Countries Involved

Microglia-synapse molecular interactions in neurodegenerative disorders

MicroSyn-MIND

Microglia are immune cells that monitor our brain and degrade unhealthy neurons and excess synapses. In Alzheimer’s disease (AD) however, microglia excessively destroy synapses, marking them as enticing treatment targets. AD patients accumulate cortical Amyloid-beta (Aβ) plaques and neurofibrillary tau tangles, whilst losing neurons and synapses...

Funding Programme
Start Date
End Date
Total Funding
€ 191 760
European Countries Involved

MiCrovasculaR rarefaction in vascUlar Cognitive Impairement and heArt faiLure

CRUCIAL

Vascular dementia and heart failure represent major health burden to morbidity, mortality and quality of life. Comorbidities (hypertension, aging, diabetes, etc.) affect all organs, but the brain and heart are especially sensitive to these chronic stresses resulting in cognitive impairment (a mental disorder) and heart failure (a non-mental...

Funding Programme
Start Date
End Date
Total Funding
€ 6 000 000
European Countries Involved

Minimally invasive endoscopes for neuronal activity monImaging-assisted single-cell specific activity monitoring and optogenetic stimulation of deep brain structures in motile and awaken animal models

WOKEGATE

Severe neuronal disorders such as dementia affect more than 1 billion people globally and account for economic burden far exceeding that of cancer. Our only chance of treating dementia is improving our understanding of how brains function at diverse levels of complexity. This will only be possible through better technologies, which already reflects...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics

MITOTARGET

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where...

Funding Programme
Start Date
End Date
Total Funding
€ 10 332 038
European Countries Involved

Mobility Safeguarding Assistance Service with Community Functionality for People with Dementia

CONFIDENCE

The aim of CONFIDENCE is to develop a community-based mobility safeguarding assistance service for people suffering from mild to moderate dementia. CONFIDENCE combines “assistive technologies” with “personal help”. The CONFIDENCE service is built around a “virtual companion” providing different levels of assistance, depending on the situational...

Funding Programme
Start Date
End Date
Total Funding
€ 2 820 158
European Countries Involved

Modelling and Inference on brain Networks for Diagnosis

MIND

Graphs are used in modern neuroscience to represent structural and functional connectivity of the brain acquired using magnetic resonance imaging. A number of pathologies affect these networks: their study holds vast promise for understanding and diagnosing brain diseases. But brain connectivity data is not trivial to process, and the predominant...

Funding Programme
Start Date
End Date
Total Funding
€ 275 363
European Countries Involved

Models of patient engagement for Alzheimer’s disease

MOPEAD

Dementia researchers are increasingly focusing their efforts on finding ways to prevent the onset of dementia symptoms in the first place, and for this they need to work with people who are still in the very earliest stages of the disease. The MOPEAD project aims to identify and test different models for engaging with this important group and...

Funding Programme
Start Date
End Date
Total Funding
€ 4 591 968
European Countries Involved

Modulating immune responses to mitigate neuroinflammation, bioenergetic decrease and cognitive decline in Alzheimer’s disease

immuno-ALZ

Background and rationale: Alzheimer's disease (AD) is the main cause of dementia, with substantial socio-economic burdens. Due to the absence of a cure, understanding disease mechanisms and developing new therapies is crucial. Age-related systemic and brain inflammation contributes to cognitive decline. Inhibiting prostaglandin 2 (PGE2) - PGE2...

Funding Programme
Start Date
End Date
Total Funding
€ 266 684
European Countries Involved

Molecular Imaging of Microglia

MIM

The societal burden of brain disorders, such as multiple sclerosis (MS), Alzheimer’s and Parkinson’s disease is enormous and is considered one of the world’s most important health challenges. They affect millions of people worldwide and the annual healthcare costs are high and are increasing with the aging population. There is an immediate need to...

Funding Programme
Start Date
End Date
Total Funding
€ 175 572
European Countries Involved

Molecular mechanism of amyloid β aggregation

MAMBA

Generation of toxic oligomers during aggregation of amyloid beta peptide (Abeta42) into amyloid fibrils is a central event in Alzheimer disease. Understanding the aggregation process is therefore one important step towards therapy and diagnosis of the disease. We propose a physical chemistry approach with the goal of finding the molecular...

Funding Programme
Start Date
End Date
Total Funding
€ 2 499 920
European Countries Involved

Molecular mechanisms of presynaptic plasticity

PreSynPlast

The ambitious goal of this project is to reveal the molecular mechanisms of presynaptic plasticity in the vertebrate brain. Synaptic plasticity occurs in the form of alterations in both presynaptic neurotransmitter release and postsynaptic receptor function. However, due to technical reasons and in contrast to intensely studied postsynaptic...

Funding Programme
Start Date
End Date
Total Funding
€ 1 609 937
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).